Clinical Trial Update: Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate [Phase 2]

View source ↗

Summary

Phase 2 safety study of SCIO-469 in patients with active rheumatoid arthritis taking methotrexate has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• SCIO-469

Snippet

Sponsor: Scios, Inc. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED